In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Myriad Genetics, Inc (NASDAQ: MYGN) closed at $15.71 in the last session, up 1.42% from day before closing price of $15.49. In other words, the price has increased by $1.42 from its previous closing price. On the day, 1.03 million shares were traded. MYGN stock price reached its highest trading level at $16.1499 during the session, while it also had its lowest trading level at $15.58.
Ratios:
We take a closer look at MYGN’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.73 and its Current Ratio is at 1.90. In the meantime, Its Debt-to-Equity ratio is 0.20 whereas as Long-Term Debt/Eq ratio is at 0.18.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on September 19, 2024, initiated with a Equal-Weight rating and assigned the stock a target price of $32.
On August 28, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $35.
On June 27, 2024, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $29.Scotiabank initiated its Sector Outperform rating on June 27, 2024, with a $29 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 11 ’24 when DIAZ PAUL J sold 15,000 shares for $22.93 per share. The transaction valued at 343,950 led to the insider holds 962,378 shares of the business.
DIAZ PAUL J bought 15,000 shares of MYGN for $343,950 on Oct 11 ’24. On Aug 21 ’24, another insider, Ancona Margaret, who serves as the Officer of the company, bought 11,538 shares for $27.82 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MYGN now has a Market Capitalization of 1430162944 and an Enterprise Value of 1473363456. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.78 while its Price-to-Book (P/B) ratio in mrq is 1.95. Its current Enterprise Value per Revenue stands at 1.789 whereas that against EBITDA is -43.462.
Stock Price History:
Over the past 52 weeks, MYGN has reached a high of $29.30, while it has fallen to a 52-week low of $14.72. The 50-Day Moving Average of the stock is -28.64%, while the 200-Day Moving Average is calculated to be -32.83%.
Shares Statistics:
According to the various share statistics, MYGN traded on average about 791.28K shares per day over the past 3-months and 995160 shares per day over the past 10 days. A total of 89.90M shares are outstanding, with a floating share count of 87.61M. Insiders hold about 3.76% of the company’s shares, while institutions hold 100.15% stake in the company. Shares short for MYGN as of 1730332800 were 4482742 with a Short Ratio of 5.67, compared to 1727654400 on 4190757. Therefore, it implies a Short% of Shares Outstanding of 4482742 and a Short% of Float of 6.909999999999999.
